Duke University OCT Eye Surgery Trial Recruiting in 2026
A Duke University study using microscope-integrated OCT for eye surgery is recruiting participants in 2026 to assess image capture and surgical outcomes.
A clinical trial at Duke University is currently recruiting participants to test microscope-integrated optical coherence tomography (MIOCT) during eye surgery. The study, titled Intraoperative OCT Guidance of Intraocular Surgery II, was observed in the ClinicalTrials.gov registry on October 19, 2026. It aims to evaluate how well this imaging technology can capture and assess ocular structures during procedures.
The research includes three groups: healthy ocular health participants, surgeons acting as research subjects, and surgical patients. All groups will undergo imaging using the same MIOCT device integrated into surgical microscopes. The trial does not have a specified phase and is sponsored by Duke University.
Study Goals and Measurements
The primary outcomes focus on the ability and quality of image capture using MIOCT during surgery. Researchers will assess whether clear images of the retina and cornea can be obtained and graded by a masked expert based on standard anatomy and pathology detection.
Additional goals include comparing retinal vascular flow seen in OCT angiography to traditional fluorescein angiography, evaluating changes in ocular blood flow and morphology before and after surgical steps, and estimating subretinal fluid volume in retinal detachment cases by comparing surgeon judgment with OCT-derived measurements.
Timeline and Status
The study has not yet posted results, and its primary completion date is estimated for December 31, 2026. This date is labeled as an estimate in the registry. The overall status remains active recruiting, indicating enrollment is ongoing.
As a registry observation, this record reflects the study’s status as reported on ClinicalTrials.gov and does not confirm final outcomes. The trial is part of a broader set of cancer-related breakthroughs signals monitored in 2026, though it focuses on ophthalmic surgery rather than oncology.